|
News for: |
|
You will land on a page at the National Library of Medicine where you can drill down to consumer info, research citations, product labelling, toxicology and more. FindingHealthOnline is the world's leading health-pharma search portal and decision engine. It helps you drill down to very detailed information without interference from commercial sites that now dominate Bing, Google, and Yahoo. Near the top of our pages, you will find a link to content that best matches your query.
|
|
|
FDA Approval Activities for this Drug…
COPEGUS (ribavirin) Tablets, 200 mg Hoffmann-La Roche NDA 21-511 Rebetol (ribavirin) Capsules, Schering NDA 20-903/S32 10/10/03 10/16/03 10/16/03 Rebetol (ribavirin) Capsules, Schering NDA 20-903/S028 6/9/03 7/8/03 7/8/03 Rebetol (ribavirin) Capsules, Schering NDA 20-903/S025 11/13/02 7/31/03 Rebetol (ribavirin) Capsules, Schering NDA 20-903/S023 9/3/02 9/5/02 Rebetol (ribavirin) Capsules, Schering NDA 20-903/S020 3/6/02 3/12/02 Rebetol (ribavirin) Capsules Schering NDA 20-903/S013 12/28/01 2/12/01 Rebetol (ribavirin) Solution, Schering NDA 21-546 7/29/03 8/6/03 8/6/03 Rebetol Rebetron Combination Therapy, Schering NDA 20-903/S030 7/9/03 7/10/03 7/9/03 Rebetol (ribavirin)/Intron A (interferon alfa-2b) (Rebetron Combination Therapy Schering NDA 20-903/S015 2/21/02 2/21/02 Rebetol (ribavirin)/Intron A (interferon alfa-2b) (Rebetron Combination Therapy Schering NDA 20-903/S008, S011, S012 & S016 7/25/01 7/26/01 7/26/01 Rebetol (ribavirin)/Intron A (interferon alfa-2b, recombinant) Schering NDA 20-903 6/3/98 6/3/98 6/3/98 9/7/01 Rebetol Indication:Treatment of chronic hepatitis C in patients with compensated liver disease who have relapsed following alpha interferon therapy. Rebetron Combination Therapy, Schering-Plough NDA 20-903/ S-025 11/13/02 11/18/02 Rebetron Combination Therapy (Rx only)consisting of Rebetol (ribavirin)200mg capsules and Intron A (interferon Alfa-2b, recombinant)3 million IU injectable Schering-Plough NDA 20-903/ S-001/S-002 12/9/98 12/14/98 12/9/98 Rebetron Combination Therapy [SCH 30500 - Intron A (Interferon alfa-2b, recombinant) for Injection/ SCH 18908 - Ribavirin]., Schering-Plough NDA 20-903/S-006 & S-007 RIBAVIRIN Capsule; 200MG REBETOL SCHERING PLOUGH RES 020903 RIBAVIRIN Capsule; 200MG ***SEE 23RD ANNUAL OB SECTION 1.8 DESCRIPTION OF SPECIAL SITUATIONS: RIBAVIRIN ORAL 200MG CAPSULE*** REBETOL SCHERING PLOUGH RES 018859 RIBAVIRIN For Solution; Inhalation 6GM/VIAL VIRAZOLE ICN 021546 RIBAVIRIN Solution; 40MG/ML REBETOL SCHERING 021511 RIBAVIRIN Tablet; 200MG COPEGUS ROCHE Ribasphere (Ribavirin) Capsules, Three River Pharmaceuticals Ribavirin Capsules, Sandoz, Inc. Copegus (RIBAVIRIN), Hoffman-La Roche Inc. Rebetron Combination Therapy, Schering Corporation Rebetol and Rebetron Combination Therapy, Schering Corporation | Ribavirin Capsule, Teva Pharma, Tentative Approval | Ribavirin Capsules, Teva Pharma, Approval | Copegus (ribavirin) tablets, Hoffmann-La Roche, New or Modified Indication | COPEGUS (ribavirin, USP) Tablets, Hoffmann-La Roche, Formulation Revision | Copegus (ribavirin) in combo w/Pegasys (peginterferon alfa-2a), Hoffman-La Roche, Labeling Revision | Copegus (ribavirin) in combo w/Pegasys (peginterferon alfa-2a), Hoffman-La Roche, Labeling Revision | Ribavirin Tablets, Teva Pharma, Approval | Ribavirin Tablets, Three Rivers Pharma, Tentative Approval | Ribavirin Capsules, Zydus Pharma, Approval | Copegus (ribavirin) Tablets, Hoffman-La Roche, Labeling Revision | Ribvirin Tablets, Teva Pharma, Approval | Ribvirin Tablets, Three Rivers Pharma, Approval | Ribvirin Tablets, Zydus Pharma, Approval | Rebetol Capsule, Schering Plough, Labeling Revision | Ribavirin Tablets, Sandoz, Inc., Approval
|